NICE has reversed a long-standing block on using Glivec in GIST tumours, saying new evidence has persuaded it to change its mind.Final draft guidance published today proposes to recommend Novartis' Glivec... Read more
The Food and Drug Administration (FDA) told the US Congress yesterday it is working hard to clarify the framework for bringing experimental therapies and vaccines to patients affected by Ebola,... Read more
Clinical Professionals Group Launches Graduate Training Academy
The Clinical Professionals Group is known for their innovation and added value services to Life Sciences and is delighted to announce the launch of their unique Life Sciences Graduate Academy.
With staff turnover in some core roles in clinical drug development at 29% attrition and increasing, Clinical Professionals wanted to take a pro-active role to provide a solution to an ever growing issue. The Life Sciences Graduate Academy is designed to identify, fully fund and train the most talented Life Sciences Graduates.
On completion of the industry leading training program, graduates are deployed into “first to industry” job roles (Clinical Trial Associate / Clinical Research Associate positions). To ensure ease of transition into industry, graduate trainees will have access to a mentor and a continued professional development program to support them during the crucial initial 12 months provided by Clinical Professionals, ensuring no additional strain on a CRO or pharmaceutical organisations’ training departments. The training provided is free of charge to both the client and graduates*.
By taking a pro-active approach to identifying, funding and training high calibre science graduates, the Clinical Professionals’ Graduate Academy will help increase the number of new highly trained professionals entering the life science industry for the first time, therefore having a positive impact on retention by offering a new pool of talented, high quality candidates.
The Graduate Training Academy will provide the option for graduates to progress from a CTA onto a CRA course, if appropriate for the individual, and all successful graduates will receive a retention bonus after 12 months of continuous employment to assist with retention and minimise turnover for the client.
To find out more about Clinical Professionals’ Graduate Academy, please contact a member of our team at email@example.com or visit the link below:
Synergy Vision's Ffyona Dawber is a finalist in the 11th Annual Stevie® Awards for Women in Business
Ffyona Dawber, Managing Director and founder of Synergy Vision, has been selected as a finalist at this year’s 11th Annual Stevie® Awards for Women in Business, in the prestigious categories of “Female Entrepreneur of The Year” and “Woman of The Year.”
The Stevie Awards for Women in Business honour women executives, entrepreneurs, employees and the companies they run – worldwide. The Stevie Awards have been hailed as the world’s premier business awards. Michael Gallagher, founder and president of the Stevie Awards said “The first-round judges have told us how delighted they are with this year’s field of Finalists.” Across all categories, a staggering 1,200 entries were submitted this year for consideration, so it is a significant achievement for Ffyona to be shortlisted in two categories.
Gold, Silver and Bronze Stevie Award winners will be announced during a gala event at the Marriott Marquis Hotel in New York on Friday, November 14. Nominated women executives and entrepreneurs from the U.S.A. and several other countries are expected to attend. The event will be broadcast live on radio in the U.S.A. (and simulcast worldwide) by Biz Talk Radio, and taped for a later television broadcast.
Ffyona established the medical communications agency Synergy Vision in 2007 and has always aimed for success. A former clinical development specialist with many years’ experience in the pharmaceutical industry, Ffyona identified a gap in the market for a full-service medical communications agency that understands first-hand the challenges faced by pharmaceutical clients. “When I created Synergy Vision I wanted trust and good client relationships to be the main focus.” This ethos remains a strong driver of the company’s growth and success.
Sorcha Ferris was one of the first SV team members, who now heads up the Dublin-based sister company SVRx. Sorcha explains why Ffyona’s vision inspired her to join the company, “As a former colleague in the pharma industry, I was inspired by Ffyona’s vision to create an agency with a strong commitment to the client, and was keen to become a part of this unique approach.”
Today, the 30-strong team at Synergy Vision, handpicked for their pharma and agency experience, solid communications know-how, passion for science and events management flair, go the extra mile to deliver the difference to their clients. Synergy Vision strive to become a trusted partner to their clients, and are considered by many to be an extension of their team.
To be a finalist in not just one, but two categories in the Stevie Awards: “Female Entrepreneur of The Year” and “Woman of The Year” reflects Ffyona’s dedication to creating and developing strong and trusted relations, both in-house and with pharma clients, and marks another exciting event in the Synergy Vision calendar!
M3 – the global provider of technology services in healthcare – has scooped the PM Society’s ‘Digital Sales Aid Award’,* for a campaign run in partnership with Rosemont and its agencies - MSA Media and Rainmaker Advertising.
The campaign, which was designed to overcome the common industry marketing problem of limited doctor engagement with pharma-owned websites, generated a 179% increase in sales, year on year, for Rosemont’s liquid formulation of Alendronic acid, for the period of the campaign.
During that period more than 5,000 unique GPs engaged with the Rosemont ImpactZone eDetail on osteoporosiswith each doctor, viewing more than 10 pages and 11% of them viewing all 15 pages of content.
The results were achieved through the use of an M3 developed traffic driving service called ClinAccess, which was launched at the start of 2014 and welcomed Rosemont as its first customer. ClinAccess works via an Application-Programming Interface (API) - a 3rd party web hosting system that provides a seamless link between Doctors.net.uk – the UK’s largest and most active online network of doctors, which is owned by M3 – and a pharma or healthcare company website.
It can cross match doctors against a target list and can be upgraded to provide more detailed information, such as changes in prescribing intentions, following a campaign.
Jan Flynn, Rosemont Marketing Manager, said: ‘Doctors.net.uk surpassed our expectations. Through them, we established a direct relationship with our key GP customers for the first time and saw it directly drive sales - far more cost effectively than if we'd deployed a GP salesforce.’
Dr Tim Ringrose, CEO of M3 (EU) said: ‘This campaign was an exciting collaboration between Rosemont Pharmaceuticals, MSA Media, Rainmaker Advertising and M3. We are thrilled that this digital programme delivered such strong results for Rosemont and we’re delighted the campaign’s success has been rewarded with the PM Society Award.’
Mary Baker, immediate past President of the European Brain Council, believes that pharma companies are focusing too much on patient centricity and instead, should widen their focus to include the whole of society. In order to solve the problems with our healthcare systems, as well as the patients, we need to look at the healthy that benefit from over the counter medicines and other members of society that are healthy at the moment but are sleep walking into illness in the future.
Mary Baker will be returning as keynote speaker for the eyeforpharma Barcelona conference after an 11-year absence. Our conversation shifted between pharma’s ‘Tribes’, Shakespeare and tipping points. Most interesting, however, was her assertion that the industry is somewhat misguided in its desire to focus exclusively on patient centricity.
Mary explains that patient centricity is a narrow worldview. It is much better to focus on a company’s role in the wider health system and society.
“If pharma companies pursue that they’re solely patient led, patient focused, patient-centric, they won’t be able to deliver”.
She goes on to describe that the role of pharma must be to impact not just the sick individual but also impact the child, parent and/or partner of that individual. They are therefore not only responsible to the patient but the broader community around the patient and therefore society. Society, in fact, matters the most.
“I’m much more concerned about society - of which the patients experience is an incredibly important part, but should not be the exclusive focus.”
At the core of Mary’s assertions is the elephant in the room: we have an unsustainable health system. At present, pharma companies of the world are simply not intrinsically involved in the major health systems of Europe –they are peripheral.
“Health is viewed as a cost and this needs to be challenged and changed. Health is wealth and a healthy nation is a wealthy nation”
The root of the problem is that the pharma industry are working in primitive tribes – representing only their own opinions which are becoming further entrenched. Pharma companies need to be collaborating – not competing with one another. Novartis should not consider Pfizer its competitor and vice versa; they should consider sources of unhealthiness as their greatest foes.
Right now, anybody who gets up and speaks is doing so from their position as a payer, or a doctor, or a regulator – when actually we are all members of society and we need to act as one.
“When you have threats on the ship of health, you need all hands to deck.”
Mary’s interview with Paul Simms, Chairman of eyeforpharma, comes at a poignant time in the run up to Barcelona, March 2015 - where the leaders in commercial and patient-led pharma discuss these issues and map the future for their companies. “The purpose of the Barcelona meeting is to provide that centre of gravity that draws in all of the right people necessary to solve this problem. No individual will determine and establish pharma’s role on their own – we absolutely need to create a movement by bringing everyone together and believing in something”. As a supporter of eyeforpharma’s efforts, Mary will take the stage to further explain what the industry needs to do: “The good thing to do is start bringing people together. Working together, we can solve this.”
Eyeforpharma have just released the full line up of leaders set to speak at eyeforpharma Barcelona next year March. You can find out more information by visiting: www.eyeforpharma.com/barcelona
London/Rome, 24 September 2014 - Today, Razorfish Healthware and Stamplay announced a strategic partnership to help healthcare organizations take the lead in the mHealth revolution. Thanks to this strategic partnership,...
Razorfish Healthware and Stamplay join forces to help healthcare organizations lead the mHealth Revolution
London/Rome, 24 September 2014 - Today, Razorfish Healthware and Stamplay announced a strategic partnership to help healthcare organizations take the lead in the mHealth revolution. Thanks to this strategic partnership, Stamplay and Razorfish Healthware will collaborate to create a customized version of the platform to better serve the needs of the healthcare industry.
According to Roberto Ascione, President of Razorfish Healthware: " The attention of the healthcare industry towards mHealth is palpable, and there is no doubt this will be an area that will see a massive growth in the coming years. Helping our customers to embrace the present opportunities and partner with the health tech startups that are disrupting the industry is core to our vision. Stamplay will allow us not only to significantly optimize the app creation process for both pharmaceutical companies and healthcare providers, but will also offer an extremely viable framework to the health tech startups to rapidly deploy their solutions. Compressing time and costs to develop the server-side component will allow us to focus the client’s resources on the design of the user experience to focus on the needs of patients and physicians".
According to Nicola Mattina, co-founder of Stamplay: "Thanks to the collaboration with Razorfish Healthware, we are envisioning a version of our platform to enable large organizations in the healthcare industry to accelerate the testing and implementation of web and mobile applications that will be used by patients and doctors to for more effective prevention, improve disease management and adherence to treatment, and so on. Mobile technology will drive a massive change in healthcare systems worldwide and will bring significant social and economic benefits: we are very excited that our technology will contribute to this shift".
About Razorfish Healthware Razorfish Healthware is a global leader in digital and healthcare communications, leveraging a unique mix of insight, technology, creativity and industry savvy to deliver digital innovations, solutions and tools that drive improved health outcomes. Our deep understanding of the innovation process, human-technology interactions and the healthcare ecosystem enables us to generate transformational experiences that empower people’s health and wellness decisions. Razorfish Healthware is part of Publicis Healthcare Communications Group (PHCG) and our service offering is made up of 3 specialized business units: an advisory practice, a digital communications and marketing practice and a solutions and technology practice. http://www.razorfishhealthware.com
About Stamplay Stamplay is an app platform that allows developers to streamline the creation of client-server web and mobile apps by providing a Back-end as a Service and a powerful rule engine to create the server-side business logic. Co-founded by Nicola Mattina and Giuliano Iacobelli, the company is based in Rome and London and is part of Seedcamp from September 2013. http://stamplay.com